An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose, crossover oral bioequivalence study of Test product (T), Lisdexamfetamine Capsules 70 mg of Granules India Limited, India and Reference product (R), Elvanse (lisdexamfetamine) 70 mg Hard Capsules of Takeda Pharmaceuticals International AG Ireland Branch, Ireland in normal, healthy, adult, human trial participants under fasting condition. - Nil

Start Date10 Jun 2026

Sponsor / Collaborator

Granules India Ltd.

CTIS2025-521224-29-00

/ CompletedPhase 1

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 70 mg, manufactured by Sun Pharmaceutical Industries Limited, India with VENVANSE (lisdexamfetamine dimesylate) 70 mg Hard Gelatin Capsule, imported and registered by: Takeda Pharma Ltd. Rodovia SP 340 S/N, km 133.5, Ed. Adm. Jaguariúna-SP CNPJ 60.397.775/0001-74 and manufactured by: Patheon Pharmaceuticals Inc. Cincinnati, United States of America or Takeda Pharma Ltd. Rodovia SP 340 S/N, km 133.5, Ed. QC - Jaguariúna – SP, Brazilian industry in healthy adult, human subjects under fasting condition.

Start Date20 Feb 2026

Sponsor / Collaborator

Sun Pharmaceutical Industries Ltd.

NCT07314333

/ CompletedPhase 1

A Phase 1, Single Blind, Parallel-arm Trial to Assess the Potential for Pharmacodynamic Interaction of Centanafadine When Co-administered With Stimulants in Healthy Adults

This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.

Start Date05 Feb 2026

Sponsor / Collaborator

Otsuka Pharmaceutical Development & Commercialization, Inc.

100 Clinical Results associated with Lisdexamfetamine Dimesylate

100 Translational Medicine associated with Lisdexamfetamine Dimesylate

100 Patents (Medical) associated with Lisdexamfetamine Dimesylate

643

Literatures (Medical) associated with Lisdexamfetamine Dimesylate

01 Dec 2026·PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Ayahuasca treatment reduces 50-kHz ultrasonic vocalizations and modifies mesocorticolimbic monoamine neurochemistry in rats

Article

Author: de Almeida, José Guilherme Silva ; Andreatini, Roberto ; Sohn, Jeferson Machado Batista ; Schwarting, Rainer ; Yonamine, Maurício ; Vieira, Gabriella Honorio ; Stern, Cristina Aparecida Jark ; De Souza, Camila Pasquini ; de Oliveira Guaita, Gisele ; de Rosso, Vinicius Theiss ; Silveira, Gabriela O ; Daneluz, Daiane Momo

Rats emit 50-kHz ultrasonic vocalizations (USVs), a widely used measure of drug-induced motivational and affective effects and dopaminergic activity. Although psychedelic drugs are promising for addiction treatment, the effects of ayahuasca (AYA) on 50-kHz ultrasonic vocalizations (USVs) remain unclear. We investigated whether acute AYA treatment attenuates lisdexamfetamine (LDX)-induced USVs, hyperlocomotion and monoaminergic content in adult male Wistar rats. Rats were pretreated with vehicle (VEH) or LDX (10 mg/kg). Forty minutes later, they received VEH or AYA (240 mg/kg) treatment. Behavioral testing was conducted 20 min later in a previous habituated arena during 20 min. Nucleus accumbens (NAc) and medial prefrontal cortex (mPFC) were dissected for monoaminergic content analysis by HPLC. AYA treatment reduced the numbers of total 50-kHz, trill and flat USV in VEH and LDX-pretreated groups, with a greater effect size in trill calls. Additionally, AYA attenuated spontaneous locomotion without affecting the LDX-induced hyperlocomotion. The pretreatment with LDX or that with AYA increased the dopamine content in the NAc, but only AYA treatment reduced DOPAC content. All treatments reduced dopamine turnover, as indicated by the DOPAC/dopamine ratio. In the mPFC, AYA treatment increased noradrenaline and decreased serotonin levels without changing their turnover. Both AYA and LDX increased dopamine turnover without altering dopamine content, and AYA did not alter the effects of LDX. Together, these findings suggest that AYA attenuates LDX-induced positive affective responses without reducing hyperlocomotion, accompanied by changes in noradrenaline and serotonin levels in the mPFC and dopamine levels in the NAc.

01 Dec 2026·JOURNAL OF AFFECTIVE DISORDERS

Pooled analysis assessing the efficacy and safety of amphetamine derivative adjunctive therapy for bipolar depression

Article

Author: Nunez, Nicolas ; Mori, Nicole ; Ozerdem, Aysegul ; Georgiev, Georgi ; Singh, Balwinder ; Biernacka, Joanna M ; Pazdernik, Vanessa K ; Frye, Mark A ; Veldic, Marin ; Cuellar-Barboza, Alfredo B ; Ali, Dina N ; Lindstrom, Karin ; Sanchez-Ruiz, Jorge A ; McElroy, Susan L

OBJECTIVE:

The bipolar pharmacopoeia targeting depression is significantly underdeveloped. Despite high rates of attention deficit symptoms, there has been inadequate investigation of stimulants as a treatment intervention for adults with bipolar depression.

METHODS:

Data were pooled from two, 8-week, randomized, placebo-controlled trials of adjunctive mixed d-amphetamine/l-amphetamine salt (MAS) and lisdexamfetamine (LDX). The primary outcome measure was baseline-to-endpoint change in the Montgomery-Asberg Depression Rating Scale (MADRS). Secondary outcomes included treatment response and remission (50%MADRS reduction, MADRS < 10), and improvement as measured by the Clinical Global Impression for Bipolar Disorder (CGI-BP). The primary safety assessment was the Young Mania Rating Scale (YMRS).

RESULTS:

Fifty-seven bipolar [BD-I: n = 23 (40.4%); BD-II: n = 34 (59.6%); male: n = 17 (29.8%); female: n = 40 (70.2%); mean age = 40.1 ± 11.3 years] depressed participants were randomized. There were no significant group differences in baseline demographics (all p ≥ 0.14). In age-adjusted analysis, participants receiving adjunctive LDX/MAS (n = 26) in comparison to placebo (n = 31) showed greater improvement in MADRS (mean % reduction: 54.6% vs. 25.6%; 95% CI: 9.1, 48.9; p = 0.005), with higher response (65.7% vs. 16.7%; p < 0.001), remission (48.8 vs. 15.3%; p = 0.007) and CGI-BP improvement rates (65.0% vs. 23.5%; p = 0.001). There was no between-group difference in YMRS scores at baseline or endpoint (p ≥ 0.36).

CONCLUSIONS:

In this pooled controlled analysis, 8-week adjunctive amphetamine was associated with reduction in depressive symptoms in carefully selected patients with bipolar depression, with no increased risk of treatment-emergent mania/hypomania. Further studies are encouraged to identify clinical correlates of treatment response guiding clinicians when to consider this potentially effective treatment.

01 Nov 2026·BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Investigating Potential Adverse Drug Reactions of Lisdexamfetamine Using Sequence Symmetry Analysis

Article

Author: Jensen, Camilla Bjørn ; Lund, Lars Christian ; Råket, Hans Kristian ; Osler, Merete ; Jimenez‐Solem, Espen ; Thysen, Sanne Møller ; Jensen, Thomas Leth ; Nielsen, Mads ; Jørgensen, Anders

ABSTRACT:

The prevalence of ADHD is increasing rapidly, and lisdexamfetamine is increasingly popular, but few studies investigate its safety. We performed a sequence symmetry analysis (SSA) using Danish register data to identify potential ADRs associated with lisdexamfetamine in 2013–2023. Outcomes were incident prescriptions or incident discharge diagnoses. We calculated trend‐adjusted sequence ratios (SR) with 95% confidence intervals (CI). We additionally performed two comparator SSAs for the same outcomes following incident use of stimulants (methylphenidate and dexamfetamine) or non‐stimulants (guanfacine and atomoxetine). This study is reported according to RECORD‐PE guidelines. We included 48 740 incident lisdexamfetamine users with a median age of 24 years (IQR 16–35). SRs were calculated for 1426 exposure–diagnosis and 1337 exposure–prescription pairs. The 50 highest SRs from each category were evaluated. Among these, 28 exposure–outcome combinations had a 95% CI lower bound above 1. Of the 100 outcomes, 33 were considered known ADRs, while 60 were previously unknown. Two outcomes indicating increased urinary symptoms were identified (‘hematuria’, SR: 1.88 [95% CI: 1.25; 2.85] and ‘other urinary symptoms’, SR: 1.63 [1.20; 2.23]). We also identified serious gastrointestinal outcomes as a potential safety alert. Further investigation into these symptoms as potential ADRs is warranted.

122

News (Medical) associated with Lisdexamfetamine Dimesylate

02 Oct 2026

·www.prnewswire.com

Samfara completes acquisition of Chr. Olesen Synthesis, Danish manufacturer of controlled-substance APIs

The acquisition is Samfara's first investment and is backed by a syndicate of European and North American institutional investors and family offices LONDON, Oct. 2, 2026 /PRNewswire/ -- Samfara, a European life sciences investment firm, today announced that it has completed the acquisition of Chr. Olesen Synthesis from Chr. Olesen and funds managed by Signet Healthcare Partners. Chief Executive Thomas Moestrup is investing alongside Samfara. Financial terms of the transaction were not disclosed. Based near Copenhagen, Chr. Olesen Synthesis develops and manufactures active pharmaceutical ingredients (APIs) and advanced intermediates, specialising in controlled substances, in particular those used to treat opioid use disorder (buprenorphine) and ADHD (lisdexamfetamine). Its cGMP-certified plant has been in commercial production since 2015 and supplies pharmaceutical companies across Europe, North America and the Middle East. The business combines technical expertise and a high level of flexibility in serving pharmaceutical customers across its markets. With Samfara's backing, Chr. Olesen Synthesis will continue to develop its capabilities, build on its existing customers and products and expand into new markets. Jean-François Hilaire, former CEO of Unither and former EVP at Recipharm, who advised Samfara on the acquisition, will join the board of Chr. Olesen Synthesis as Chair. Helena Malchione and James Cocker, Partners of Samfara, said: "Chr. Olesen Synthesis illustrates our strategy of finding winning companies in complex niches and backing them with capital and strategic support. It holds a strong position and an excellent reputation in a demanding part of the pharmaceutical market, and we look forward to working with Thomas and the team as they grow with existing customers and expand into new markets, both organically and through acquisitions." Thomas Moestrup, Chief Executive of Chr. Olesen Synthesis, said: "This is an exciting next step for Chr. Olesen Synthesis. With Samfara as our new owner, we have a partner who shares our ambitions and will support the continued development of the business. We look forward to building on our strong customer relationships, expanding the business and developing the opportunities ahead of us." Mads C. Olesen, Chief Executive and owner of Chr. Olesen, said: "In 2011, Chr. Olesen acquired Chr. Olesen Synthesis and, together with Signet Healthcare, has built it into a significant player in controlled-substance APIs. The time is right for new owners to take the business forward, and we are confident that we have entrusted the company to the right new owner. We extend our best wishes to Samfara and the management team of the company." ADVISERS Samfara was advised by Addleshaw Goddard (legal, UK), Connaught (capital formation), infotransactions (financial and tax due diligence), Lockton (W&I insurance), Nivaro Law (legal, Denmark) and RSM (tax structuring). Chr. Olesen and Signet Healthcare Partners were advised by LEK (commercial), Moalem Weitemeyer (legal), Nielsen Nørager (legal), PwC (financial and tax), Sheppard, Mullin, Richter & Hampton (legal), and Stifel (M&A). ABOUT SAMFARA Samfara is a London-based private equity firm focused on majority buyouts of European life sciences companies in the lower mid-market. The firm makes thesis-led investments in complex, international businesses whose performance can be accelerated and transformed through active ownership. Samfara aims to deliver attractive returns for investors while supporting European life sciences companies, the jobs they create and the patients they benefit. Samfara LLP is an appointed representative of Suntera Advisers (UK) Limited, which is authorised and regulated by the Financial Conduct Authority. ABOUT CHR. OLESEN SYNTHESIS Chr. Olesen Synthesis is a Danish developer and manufacturer of APIs and advanced intermediates, specialising in controlled substances. From its cGMP-certified plant in Hvidovre, near Copenhagen, it supplies pharmaceutical companies across Europe, North America and the Middle East and offers contract development and manufacturing services for new APIs. ABOUT CHR. OLESEN Chr. Olesen, founded in 1885, is a family-owned global distribution company specializing in nutraceutical ingredients for the feed, food, pharma, and technical industries. ABOUT SIGNET HEALTHCARE PARTNERS Signet Healthcare Partners is a healthcare growth equity firm that invests in commercial-stage pharmaceutical (pharma services and therapeutics) and medical technology companies. Founded in 1998 and based in New York, Signet has invested in more than 60 companies, supporting entrepreneurs with capital, strategic guidance, and deep industry networks. CONTACTS Samfara Helena Malchione, Partner [email protected] James Cocker, Partner [email protected] Chr. Olesen Synthesis Thomas Moestrup, Chief Executive [email protected] SOURCE Samfara LLP 21% more press release views with Request a Demo

Acquisition

10 Sep 2026

·www.fiercebiotech.com

Chutes & Ladders—Longtime Takeda R&D chief to depart next June

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Donavyn Coffey, Marissa Russo and Will Maddox, and it will be featured here at the end of each week. Longtime Takeda R&D chief to depart next June Takeda President of Research and Development Andy Plump , M.D., Ph.D., is leaving the company in June after twelve years in the position. Plump joined the Japanese Big Pharma in 2015 from Sanofi, where he was chief medical and scientific officer. The executive will continue to lead R&D for Takeda until a successor is named and will help with the transition through the middle of next year. The announcement comes as Takeda looks to grow revenue at a time when its exclusivity on ADHD drug Vyvanse has dragged on sales. Last month, the FDA approved narcolepsy treatment Orzeyful and blood cancer drug Mimrylo. In the last five years, the company has won approval for the antiviral Livtencity, blood clotting disorder drug Adzynma and eosinophilic esophagitis therapy Eohilia. A trained internal medicine physician with a fellowship in medical genetics, Plump was also worldwide cardiovascular research head at Merck & Co., where he oversaw cardiovascular research, preclinical development and translational sciences. Story Sofinnova lands Gilead alum as executive partner Sofinnova Investments Biopharmaceutical investment firm Sofinnova announced the addition of Merdad Parsey , M.D., Ph.D., to the investment team as an executive partner. Parsey hails from his executive vice president and chief medical officer role at Gilead. Prior to Gilead, he held several tenure positions at other Big Pharmas such as Merck & Co., Regeneron and Genentech. “I have had the opportunity to work across early research and clinical development through regulatory approval and commercialization, with the goal of bringing innovative, important new medicines to patients,” Parsey said in the release. “I look forward to being part of the Sofinnova team to continue those efforts.” Parsey joins an already stacked Sofinnova partners team that includes Sanofi and Biogen alum Maha Radhakrishnan, M.D., Roche, Amgen and Merck leader Jonathan Leff, M.D., and Merck and GSK alum Chris Carpenter, M.D., Ph.D., among others. Since its founding, Sofinnova has built companies in the U.S. and Europe with approximately $4.8 billion in assets under management and committed capital, as of the end of June. Release Pyxis locks in interim CEO in preparation for phase 1 results Ahead of a Phase 1 readout for its first-in-class antibody drug conjugate (ADC), Pyxis Oncology has appointed its interim CEO, Thomas Civik, to a permanent appointment as CEO and chairman of the board. Civik stepped up as interim CEO in February of 2026 and has been a member of Pyxis’ board of directors since 2021. Prior to Pyxis, Civik was chairman of ImCheck Therapeutics which sold to Ispen and Repare Therapeutics which was in turn sold to Xoma. He was also president and CEO of Five Prime Therapeutics until it was acquired by Amgen. With Civik at the helm, Pyxis co-founder and founding chairman, John Flavin , will transition to serve as lead independent director of the board. Pyxis expects to report data from its MICVO Phase 1 study in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma this fall. Release > Vaxcyte plucks former 17-year Pfizer alum Luis Jodar , Ph.D., to be its new chief medical officer as the California-based vaccine company expects topline data from the phase 3 VAX-31 OPUS-1 trial by the end of October. Vaxcyte also appointed former Teva chief legal officer David McAvoy as its new chief legal officer. Release > ADC biotech Callio Therapeutics has named Zachary Hornby as CEO. He was previously CEO, president and a director at Boundless Bio. Callio co-founder Piers Ingram , Ph.D., and former Chief Scientific Officer Jerome Boyd-Kirkup , Ph.D., will both transition to senior advisor roles. Release > Sabrina Kuttruff-Coqui , Ph.D., will be the new CEO of immunology-focused Orkine Bio. She will be joined by new Chief Scientific and Development Officer Joachim Koch , Ph.D., and Andreas Muehler , M.D., who will serve as the company’s new chief medical officer. Release > Eikon Therapeutics appointed Bristol Myers Squibb and Gilead alum, Ching-Pin Chang , M.D., Ph.D., as its executive vice president and chief scientific officer. Release > Radiopharmaceutical biotech Actithera has named Steven Kelly as its new CEO and a member of its board. He will guide the company’s fibroblast activation protein-targeted RLT into clinical development. Founder Andreas Goutopoulos will continue as president and head of research and development. Release > Huntington’s disease and ALS specialist Prilenia Therapeutics has named Frederick Munschauer III , M.D., as chief medical officer. He most recently served in the same role at Emalex Biosciences. Release > AI therapeutics company insitro has named Hideo Makimura as its new chief medical officer. He will lead the company’s AI-derived metabolic disease and neuroscience pipeline toward the clinic. Most recently, he held the same role at Affinia Therapeutics. Release > Editas Medicine appointed Dan Ory , M.D., as new chief medical officer to help advance its lead in vivo CRISPR gene editing candidate, EDIT-401, to the clinic for the treatment of hyperlipidemia. Release > Cytospire Therapeutics has called up Sumeet Ambarkhane , M.D., to be its new chief medical officer as the London-based T cell engager developer advances its lead asset, CYT X300, to clinical development as a potential treatment for EGFR-positive solid tumors. Release > Gilead and OrsoBio alum Rob Myers , M.D., joins Mirum Pharmaceuticals as new chief medical officer to help lead global medical and clinical development. Release > Med tech company Pulmera has named Stryker veteran Jared Silbeck as its new chief commercial officer to lead commercial adoption of its CBeam 3D imaging platform. Release > PMV Pharmaceuticals, a precision oncology firm, tapped Philip Herman as its new chief commercial officer. Herman will orchestrate PMV’s commercial strategy and launch of rezatapopt, PMV Pharma’s p53 reactivator, which is slated for a New Drug Application in early 2027. Release > Tonix Pharmaceuticals promoted Thomas Englese to serve as its first chief commercial officer. Englese has served as the company’s executive vice president of commercial operations since 2024. Release

Drug ApprovalExecutive ChangePhase 1Vaccine

10 Sep 2026

·www.fiercebiotech.com

Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

Andy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June. Plump joined the Japanese drugmaker in 2015, arriving from Sanofi to initially serve as chief medical and scientific officer. Now, Plump has announced plans to retire from Takeda. The executive will continue to lead the R&D team until a successor is appointed and will then work with the new leader to smooth the transition before leaving the company next year. News of Plump’s departure follows the development of molecules intended to drive growth at Takeda after a period in which the loss of exclusivity on ADHD drug Vyvanse dragged on sales. Last month, the company won FDA approvals for narcolepsy treatment Orzeyful and blood cancer drug Mimrylo . Having recently shared positive phase 3 data on zasocitinib in psoriasis, Takeda is poised to add the TYK2 inhibitor to its stable of recently approved medicines. Since 2021, the company has won approval for the antiviral Livtencity , the blood clotting disorder drug Adzynma and the eosinophilic esophagitis therapy Eohilia . Plump’s successor will inherit the challenge of continuing to launch new growth drivers to offset the loss of exclusivity on the inflammatory bowel disease drug Entyvio. While the recent approvals point to the success of some of Plump’s preparations for competition from Entyvio biosimilars, other R&D initiatives overseen by the outgoing executive have failed to deliver the hoped-for results. Notably, Takeda’s play for the cell therapy market fizzled out, with the company exiting the modality last year and taking an impairment loss on its 2021 takeover of GammaDelta Therapeutics. A Crohn’s disease cell therapy, Alofisel, which Takeda acquired in its takeover of TiGenix, reached the European market but was withdrawn in the aftermath of a phase 3 failure .

Phase 3Cell TherapyExecutive ChangeDrug ApprovalAcquisition

100 Deals associated with Lisdexamfetamine Dimesylate

External Link

KEGG	Wiki	ATC	Drug Bank
D04747	Lisdexamfetamine Dimesylate	N06BA12	DB01255

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Binge-Eating Disorder	United States	Takeda Pharmaceuticals U.S.A., Inc.	30 Jan 2015
Feeding and Eating Disorders	Canada	Takeda Pharmaceutical Co., Ltd.	14 Apr 2010
Attention Deficit Disorder With Hyperactivity	United States	Takeda Pharmaceuticals U.S.A., Inc.	23 Feb 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Schizophrenia	Phase 3	-	Shire Plc	27 Jan 2012
Depressive Disorder, Major	Phase 3	United States	Shire Plc	19 Oct 2011
Depressive Disorder, Major	Phase 3	Belgium	Shire Plc	19 Oct 2011
Depressive Disorder, Major	Phase 3	Czechia	Shire Plc	19 Oct 2011
Depressive Disorder, Major	Phase 3	Estonia	Shire Plc	19 Oct 2011
Depressive Disorder, Major	Phase 3	Finland	Shire Plc	19 Oct 2011
Depressive Disorder, Major	Phase 3	Germany	Shire Plc	19 Oct 2011
Depressive Disorder, Major	Phase 3	Hungary	Shire Plc	19 Oct 2011
Depressive Disorder, Major	Phase 3	Poland	Shire Plc	19 Oct 2011
Depressive Disorder, Major	Phase 3	Romania	Shire Plc	19 Oct 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04599504 (CTgov)	Phase 2/3	Fecal Incontinence \| Overweight	16	Lisdexamfetamine Dimesylate (Medication) (Lisdexamfetamine Dimesylate)	kealkuzydz(hhrncwlyzz) = zlzsolkaim mcbwlvhtin (gnhmmhmcld, 6.72) View more	-	06 Aug 2026
				Placebo (Placebo)	kealkuzydz(hhrncwlyzz) = urzwncladl mcbwlvhtin (gnhmmhmcld, 10.31) View more
NCT03924193 (Pubmed \| Int J Eat Disord)	Phase 3	Binge-Eating Disorder	141	Cognitive-Behavioral Therapy (CBT)	bligaytyzp(hruwiqcskl) = lmvivzpvcc egolilrqwb (wcdwrvmqbr ) View more	Positive	01 Aug 2026
				Lisdexamfetamine (LDX)	bligaytyzp(hruwiqcskl) = ggougssxpj egolilrqwb (wcdwrvmqbr ) View more
NCT03926052 (CTgov)	Phase 3	Binge-Eating Disorder \| Obesity	61	Placebo	kxhzyrlcny = ulkbzjlahm suwdwyftps (qcaljwmkur, npxwnvaerx - jsvadmvfqq) View more	-	17 Dec 2025
FDA_CDER Manual	Not Applicable	Binge-Eating Disorder	-	Lisdexamfetamine dimesylateLisdexamfetamine dimesylate (50 mg or 70 mg/day) (Study 11)	rwpyqojpwq(djvelsrfta) = qnbmhlcugb vpjkwvfqho (rjrmdabyka, 0.12)	Positive	16 Jun 2025
				Placebo (Study 11)	rwpyqojpwq(djvelsrfta) = qmapfjpchv vpjkwvfqho (rjrmdabyka, 0.13)
FDA_CDER Manual	Not Applicable	Attention Deficit Disorder With Hyperactivity	-	Lisdexamfetamine dimesylateLisdexamfetamine dimesylate (30 mg/day) (Study 1 + 6 – 12years)	jkujksnckf(newnqoolwl) = nnvstgugdz velluwfmut (iivbdrxonv, 1.6)	Positive	16 Jun 2025
				Lisdexamfetamine dimesylateLisdexamfetamine dimesylate (50 mg/day) (Study 1 + 6 – 12years)	jkujksnckf(newnqoolwl) = txdxirhpgs velluwfmut (iivbdrxonv, 1.6)
NCT05854667 (ASCME, Pubmed \| Contemp Clin Trials)	Phase 3	Methamphetamine abuse	440	Lisdexamfetamine 250 mg (Treatment-as-usual + Contingency management)	jcsjwxrgkf(lcahgyrrld) = gtkqkohuni babvuoyymi (vxxakdohle ) View more	Positive	01 Jun 2025
				Lisdexamfetamine 250 mg (Treatment-as-usual)	jcsjwxrgkf(lcahgyrrld) = mlkmwzuyks babvuoyymi (vxxakdohle ) View more
NCT03924193 (Pubmed \| J Clin Psychiatry)	Phase 3	Binge-Eating Disorder	102	Lisdexamfetamine	rykrarmloi(splayirboq) = ucqgzntqyz zrnchndyhs (zyeqrccjhi )	-	07 May 2025
				Cognitive Behavioral Therapy	rykrarmloi(splayirboq) = untipqqmne zrnchndyhs (zyeqrccjhi )
NCT03924193 (CTgov)	Phase 3	Binge-Eating Disorder \| Obesity	141	Cognitive-Behavioral Therapy (Cognitive-Behavioral Therapy)	lohfxedqpp(njsmatdbfr) = vkljzqadju sxifzowhpj (gdllebiezx, 5.88) View more	-	17 Oct 2024
				Combination LDX and Cognitive-Behavioral Therapy (LDX and Cognitive Behavioral Therapy)	lohfxedqpp(njsmatdbfr) = jwbzfyeeym sxifzowhpj (gdllebiezx, 2.67) View more
NCT03187353 (IMPRES, CTgov)	Phase 4	Cognitive Dysfunction	69	Lisdexamfetamine (Lisdexamfetamine (Per Intervention))	fzzuangzip(svkcxaghze) = izhxtdntbz yvckaqomiz (ejlqgqfikk, rlmasjsbym - zlxkqgzohy) View more	-	18 Nov 2023
				Placebo (Placebo (Per Intervention))	fzzuangzip(svkcxaghze) = nzklrmtdbj yvckaqomiz (ejlqgqfikk, xgeamvtawg - kjhkgdouda) View more
NCT02259517 (CTgov)	Not Applicable	Attention Deficit Disorder With Hyperactivity	38	Guanfacine (Guanfacine)	rlhrfogpav(powvowswpj) = vhsapkuqut xaihlryrfe (tuafigbfts, jnuyytsbzx - jggnpkxgxe) View more	-	02 Feb 2023
				Lisdexamfetamine (Lisdexamfetamine)	rlhrfogpav(powvowswpj) = baopkcedsv xaihlryrfe (tuafigbfts, bgbkgvamqu - uxvykdnqdj) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis